Vaginal microbiome dysbiosis and sexually transmitted infections correlate with concentrations of immunoglobulin isotypes in human cervicovaginal mucus: insights into HIV-1 transmission

阴道微生物群失调和性传播感染与人类宫颈阴道粘液中免疫球蛋白同种型的浓度相关:对 HIV-1 传播的启示

阅读:1

Abstract

INTRODUCTION: Little is known about the relationship between antibody isotype in cervicovaginal mucus (CVM) and the local microenvironment and how this impacts HIV-1 transmission at the female genital mucosa. METHODS: In a cohort of 139 adult women in Kenya, we measured antibody isotypes in CVM and describe their associations with local pH, serum concentrations of estrogen and progesterone, and sexually transmitted infections (STIs), including HIV-1. RESULTS: We found that immunoglobulin G2 (IgG2) was the most abundant and IgG4 was the least abundant in the CVM. Overall, IgG1 concentrations were significantly lower in CVM samples from women with bacterial vaginosis (BV) compared to those without BV. Among women with BV, IgG1 concentrations declined further as vaginal pH increased, suggesting possible pH-mediated degradation. We also report negative associations of BV status with IgG3 and IgG4. In addition, infection with Mycoplasma genitalium and Neisseria gonorrhoeae was positively associated with concentrations of IgA and IgM, respectively. We also found the relationship between antibody isotype and subclasses with HIV-1 viral mobility in vitro. IgG3 concentrations negatively correlated with CAP045 HIV-1 mobility and IgG1 concentrations negatively correlated with the mobility of the 92TH023 recombinant HIV-1 strain upon VRC01 depletion. These observations point towards a potentially protective role for IgG1 and IgG3 in trapping certain HIV-1 strains in the CVM. DISCUSSION: Importantly, our study builds on previous work, providing a potential mechanism by which BV and STIs may modulate immunoglobulin isotype and subclass content in the CVM. These results highlight the need for proper treatment of BV and other STIs, as this could impact the effectiveness of HIV-1 vaccines targeted at enhancing specific immunoglobulin responses in the cervicovaginal mucosa.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。